Interventional psychiatry encompasses various treatments, primarily categorized into neuromodulation techniques and interventional pharmacology. These treatments are typically employed in cases of treatment-resistant mental health disorders.
Neuromodulation techniques •
Electroconvulsive Therapy (ECT): ECT remains a cornerstone of interventional psychiatry, especially for severe, treatment-resistant depression and catatonia. The procedure involves controlled electrical currents to the brain, inducing a seizure that can lead to significant improvements in mood and behavior. •
Transcranial Magnetic Stimulation (TMS): TMS is a non-invasive technique using magnetic fields to stimulate specific brain areas. It has been approved for treating major depressive disorder and is particularly useful for patients unresponsive to antidepressants. Unlike ECT, TMS does not require anesthesia and has a lower risk of cognitive side effects. •
Vagus Nerve Stimulation (VNS): VNS involves implanting a device that delivers electrical impulses to the vagus nerve, influencing brain activity. Initially developed for epilepsy treatment, VNS has also been approved for treatment-resistant depression. •
Deep Brain Stimulation (DBS): DBS is an invasive procedure involving the surgical implantation of electrodes in specific brain areas. These electrodes deliver electrical impulses to modulate brain circuits involved in mood regulation. DBS is currently used for conditions such as Parkinson’s disease and obsessive-compulsive disorder and is being explored as a treatment for severe depression. •
Other Emerging Techniques: New modalities such as
focused ultrasound (FUS),
transcranial direct current stimulation (tDCS), and
magnetic seizure therapy (MST) are under investigation for potential psychiatric applications, offering the possibility of more targeted and less invasive interventions.
Interventional pharmacology •
Ketamine and Esketamine: Ketamine, an anesthetic, has shown rapid antidepressant effects in patients with treatment-resistant depression. It is administered intravenously in controlled settings. Esketamine, a derivative of ketamine, is available as a nasal spray and has been approved for use with oral antidepressants for treatment-resistant depression. •
Other Pharmacological Interventions: This category includes intravenous
brexanolone, used for postpartum depression, and emerging therapies involving psychedelics such as
psilocybin, which are being studied for their potential to enhance psychotherapy and treat refractory depression. == Fellowship programs ==